Phase I/II trial of a gene therapy developed by Atlantic Gene Therapies, Généthon and the Institute of Myology as a potential therapy for Duchenne muscular dystrophy.
Phase of Trial: Phase I/II
Latest Information Update: 19 Nov 2014
At a glance
- Drugs Muscular dystrophy gene therapy (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man; Therapeutic Use
- 19 Nov 2014 New trial record